Cancure
  • Home
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • News
    • Public Documents
  • Contact
  • Glossary of Terms
  • Search
  • Menu Menu
Genvax
Galectin

Combination Therapy

The majority of opinion-leading oncologists worldwide agree that combination therapy offers tremendous potential for extending the lifespan of – and ultimately curing – cancer patients. The evolution of combination immunomodulatory approaches promises to maximise treatment outcomes and overcome most tumours’ resistance mechanisms to single-agent immunotherapy.

Cancure has developed its own potential breakthrough immunotherapies. Genvax formulations specific for each target indication and Galectin CNC225 can be combined with an ICI to achieve unprecedented response rates in a range of major cancer indications, including breast and colon cancer.

The powerful combination of a Genvax formulation and Galectin CNC225 with an immune checkpoint inhibitor (anti-CTLA4) resulted in an experimental “cure” for colon cancer, with 100% survival of mice receiving the triple combination. These results are extremely compelling.

  • Genvax – lead candidate CNC118
  • Galectin – lead candidate CNC225
  • Mitocans – lead candidate CNC332
  • Combination Therapy
  • Genvax vs. CAR-T
  • Development Program
  • References

NEWS

  • NousCom receives $49M to trial off-the-shelf cancer vaccine
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
  • Incyte pays MacroGenics $150M for PD-1 inhibitor
  • Gilead buys CAR-T developer Kite Pharma for $12B

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2021 All rights reserved.
  • Twitter
  • Dribbble
Scroll to top